We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Lab21 Expands Microbiology Offering With Acquisition of Biotec

By LabMedica International staff writers
Posted on 11 Mar 2009
Lab21 (Cambridge, UK) has purchased the majority shareholding of Biotec Laboratories Ltd (Ipswich, UK), a clinical diagnostic company with emphasis on infectious diseases, particularly tuberculosis (TB). More...
As part of the sale, Lab21 also acquires Biotec's South African subsidiary, Biotec Laboratories SA (Johannesburg, South Africa), which is a joint venture with the Cape Biotech Trust. The financial terms of the deal were not disclosed and the transaction takes immediate effect. For the immediate future, Biotec Laboratories will continue to trade as a subsidiary of Lab21 group.

The acquisition expands the Lab21 microbiology product offering in infectious diseases and broadens its global distribution network. Biotec Laboratories SA, based in Johannesburg, South Africa has developed proprietary phage amplification technology that is being used to develop rapid diagnostic and susceptibility tests for both active and drug resistant TB.

Dr. Berwyn Clarke, chief scientific development officer of Lab21 commented, "We look forward to working with the R&D team of Biotec and exploring how its phage amplification technology can be used for the detection of other mycobacterium borne diseases, beyond TB. The combination of our technical and clinical skills and sector experience creates a very strong R&D group that can fuel significant new product development in both immunodiagnostics and molecular diagnostics over the coming years."

Biotec Laboratories is a rapid diagnostics business, engaged in the production and worldwide distribution of quality reagents, test kits and dehydrated culture media. Its research and development is focused on new and innovative technologies in the field of rapid amplification of bacteria, with particular emphasis on the detection of tuberculosis.

Lab21 is a global provider of diagnostic products and services, supporting drug discovery and healthcare. Its customers include healthcare providers, pharmaceutic, and biotechnology companies. The company has a growing test portfolio providing companion diagnostics and high technology assays for the growing integration of personalized medicine into healthcare.

Related Links:
Lab21
Biotec Laboratories Ltd



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.